Cohance Lifesciences Limited has informed the Exchange about Investor Presentation
COHANCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Cohance Lifesciences released its Q1FY26 investor presentation, marking the first full quarter of consolidated reporting after the merger. Revenue grew 13% YoY to INR 5,493 mn, with broad-based growth: Pharma CDMO +1% (+30% adjusted for inventory destocking), API+ +19%, and Specialty Chemicals +28%. Material (gross) margin expanded to 73% from 68.4%, but adjusted EBITDA margin fell to 23.9% from 27.6% due to planned investments in talent, NJ Bio and Sapala integration, and business development. Adjusted PAT stood at INR 629 mn (margin 11.4%). The company is net cash positive at INR 2.44 bn with INR 4.41 bn cash on books. Niche technology share crossed 20% of revenue, and the company works with 19 of the top 20 global innovators.
Margins are temporarily compressed by integration and investment costs, but strong order pipeline, niche tech growth, and capacity expansion underpin the long-term USD 1 bn revenue by 2030 target with mid-30s EBITDA margins. Short-term stock reaction may be neutral-to-negative on margin pressure, while long-term outlook remains constructive.